Switching from IV to under-the-skin infliximab after dose increase
Treatments studied
Part of Digestive system clinical trials.
This study tests if switching from a high-dose infliximab IV infusion to a daily or weekly injection under the skin works just as well. It is for people with inflammatory bowel disease who are already stable on IV infliximab.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have Crohn's disease, ulcerative colitis, or IBD unclassified.
- You are 18 years or older.
- You have been getting infliximab through a vein (IV) for at least 6 months, and your dose has been stable for at least 5 months.
- You are in remission (no symptoms) without needing steroids for at least 8 weeks.
- You do not have a stoma (bag), a pouch, or active draining fistulas near your bottom.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether people with Crohn’s disease or ulcerative colitis who are currently well-controlled can safely use less-frequent anti-TNF medicine. It may help reduce treatment intensity while keeping inflammation under control.
This study looks at whether giving infliximab as a shot under the skin, after initial IV doses, helps people with severe ulcerative colitis. It may help doctors understand if this easier way of taking the medicine works well over a year.
This trial tests a more precise way to start infliximab (a Crohn’s medicine) and adjust dosing based on how your body responds. It aims to better control Crohn’s inflammation early and keep it under control.
This study tests whether adjusting the dose of infliximab (a biologic medicine given by IV) based on drug levels in your blood works better for treating draining fistulas caused by Crohn's disease. It is for people who have not tried other biologics and whose fistulas have not healed with usual treatments.
This study tests whether a weekly/regular skin injection version of vedolizumab can help adults with moderate to severe ulcerative colitis or Crohn’s disease who did not fully respond to other treatments or TNF blockers. It may help by moving you from an intravenous (IV) infusion to a self/clinic injection option.
This study compares an existing UC medication (infliximab) with a newer one (ustekinumab) and a combination of both. The goal is to see which works best for moderate to severe UC when other treatments have failed.
Hear when a new Ulcerative Colitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.